- Home
- NWL vs NRIX Comparison
NWL vs NRIX Comparison
Compare NWL & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NWL | NRIX |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NWL | NRIX |
|---|---|---|
| Price | $3.99 | $16.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $4.97 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 6.5M | 691.1K |
| Earning Date | 05-01-2026 | 04-08-2026 |
| Dividend Yield | ★ 7.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,742,200,000.00 | $76,987,000.00 |
| Revenue This Year | $1.19 | N/A |
| Revenue Next Year | $1.58 | $48.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.14 | ★ 99.31 |
| 52 Week Low | $3.07 | $8.20 |
| 52 Week High | $6.64 | $22.50 |
Technical Indicators
Market Signals| Indicator | NWL | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 45.55 |
| Support Level | $3.22 | $15.22 |
| Resistance Level | $4.47 | $16.71 |
| Average True Range (ATR) | 0.22 | 0.77 |
| MACD | -0.05 | -0.12 |
| Stochastic Oscillator | 14.12 | 16.78 |
Price Performance
Historical ComparisonAbout NWL Newell Brands Inc.
Newell Brands Inc is an American consumer goods company with a portfolio of brands, including Rubbermaid, Sharpie, Graco, Coleman, Rubbermaid Commercial Products, Yankee Candle, Paper Mate, FoodSaver, Dymo, EXPO, Elmer's, Oster, NUK, Spontex and Campingaz. The group is focused on delighting consumers by lighting up everyday moments. Its segments are Home and Commercial Solutions, Learning and Development, and Outdoor and Recreation. The group geographic areas are the United States, Canada, Europe, the Middle East and Africa, Asia Pacific, and Latin America.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.